ArticleWorld journal of cardiology2024
Nicorandil as a promising therapeutic option for ventricular arrhythmia: A case report and review of literature.
Article in World journal of cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVentricular arrhythmia is a common type of arrhythmia observed in clinical practice. It is primarily characterized by premature ventricular contractions, ventricular tachycardia, and ventricular fibrillation. Abnormal formation or transmission of cardiac electrical impulses in patients affects cardiac ejection function. It may present with symptoms such as palpitations, dyspnea, chest discomfort, and reduced exercise tolerance. In severe cases, ventricular arrhythmia can even lead to death. Therefore, prompt treatment is very much essential upon diagnosis. The symptoms did not improve after previous conventional drugs and electrical defibrillation treatment, but the ventricular arrhythmia was prevented after the addition of nicorandil. CASE SUMMARY: A 75-year-old female patient was admitted to the hospital because of intermittent chest tightness, shortness of breath for 10 days, and fainting once for 7 days. Combined with laboratory tests and auxiliary examination, the patient was tentatively diagnosed with coronary heart disease or arrhythmia-atrial fibrillation. After admission, the patient had intermittent ventricular arrhythmia, which was uncontrolled with lidocaine, defibrillation, and amiodarone. However, when she was treated with nicorandil, the ventricular arrhythmia stopped. Nicorandil mitigates the action potential duration by facilitating the opening of potassium ion channels, thereby regulating the likelihood of premature and delayed depolarization in two distinct phases and subsequently averting the onset of malignant ventricular arrhythmia. Nicorandil may inhibit ventricular arrhythmia by dilating coronary arteries, improving coronary microcirculation and reducing myocardial fibrosis.
conclusionNicorandil is a drug with dual effects. It could be used as a new therapeutic option for inhibiting ventricular arrhythmias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.